All In Biotech

Drug Trial Radar · NCT05199753

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Mar 16, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
LaNova Australia Pty LimitedIndustry
Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-108Drug

    Administered intravenously

  • An Anti-PD-1 AntibodyDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 126 weeks
  2. Incidence of dose-limiting toxicity (DLT)Time frame: 126 weeks
  3. Incidence of serious adverse event (SAE)Time frame: 126 weeks
  4. Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.Time frame: 126 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Sydney, New South Wales, Australia

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, Australia

  • ICON Cancer Centre

    South Brisbane, Queensland, Australia

  • Cabrini Health Limited

    Malvern, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • One Clinical Research Pty Ltd.

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.